Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Descending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
60505-6095-00 60505-6095 Bendamustine Hydrochloride Bendamustine Hydrochloride 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 19, 2023 In Use
60505-6068-00 60505-6068 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
60505-6067-00 60505-6067 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
60505-6066-00 60505-6066 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
60505-6065-00 60505-6065 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
60505-6050-04 60505-6050 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
60505-4764-06 60505-4764 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral July 16, 2021 In Use
60505-4631-03 60505-4631 Cyclosporine CycloSPORINE, Modfied 50.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Nov. 5, 2019 Aug. 31, 2023 In Use
60505-4630-03 60505-4630 Cyclosporine CycloSPORINE, Modfied 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Nov. 5, 2019 Aug. 31, 2023 In Use
60505-4537-02 60505-4537 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
60505-4537-01 60505-4537 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 March 8, 2023 In Use
60505-4536-02 60505-4536 Lenalidomide Lenalidomide 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 9, 2023 In Use
60505-4535-02 60505-4535 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
60505-4535-01 60505-4535 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 March 8, 2023 In Use
60505-4534-02 60505-4534 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
60505-4534-01 60505-4534 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 March 8, 2023 In Use
60505-4533-02 60505-4533 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
60505-4533-01 60505-4533 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 March 8, 2023 In Use
60505-4532-02 60505-4532 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 9, 2023 In Use
60505-4512-03 60505-4512 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 8, 2023 In Use
60505-4327-03 60505-4327 Abiraterone Acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Nov. 23, 2018 Aug. 11, 2021 In Use
60505-4327-01 60505-4327 Abiraterone Acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Nov. 23, 2018 In Use
60505-3877-09 60505-3877 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Nov. 25, 2015 Jan. 31, 2021 No Longer Used
60505-3877-03 60505-3877 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Nov. 25, 2015 Jan. 31, 2021 No Longer Used
60505-3255-08 60505-3255 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 31, 2012 May 31, 2019 No Longer Used
60505-3255-03 60505-3255 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 31, 2012 Dec. 31, 2021 No Longer Used
60505-3255-01 60505-3255 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 31, 2012 May 31, 2019 No Longer Used
60505-3036-07 60505-3036 Tamoxifen Citrate Tamoxifen Citrate Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 30, 2012 Dec. 1, 2012 No Longer Used
60505-3036-03 60505-3036 Tamoxifen Citrate Tamoxifen Citrate Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 30, 2012 Dec. 1, 2012 No Longer Used
60505-3036-01 60505-3036 Tamoxifen Citrate Tamoxifen Citrate Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 30, 2012 Dec. 1, 2012 No Longer Used
60505-3035-07 60505-3035 Tamoxifen Citrate Tamoxifen Citrate Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 30, 2012 Dec. 1, 2012 No Longer Used
60505-3035-06 60505-3035 Tamoxifen Citrate Tamoxifen Citrate Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 30, 2012 Dec. 1, 2012 No Longer Used
60505-3035-05 60505-3035 Tamoxifen Citrate Tamoxifen Citrate Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 30, 2012 Dec. 1, 2012 No Longer Used
60505-3035-03 60505-3035 Tamoxifen Citrate Tamoxifen Citrate Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 30, 2012 Dec. 1, 2012 No Longer Used
60505-2985-03 60505-2985 Anastrozole Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 31, 2012 March 1, 2021 No Longer Used
60505-2901-09 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-05 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-03 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-01 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-00 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-09 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-08 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-03 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-01 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-00 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2710-08 60505-2710 Granisetron Hydrochloride Granisetron Hydrochloride Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 27, 2008 Dec. 1, 2008 No Longer Used
60505-2710-02 60505-2710 Granisetron Hydrochloride Granisetron Hydrochloride Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 27, 2008 Dec. 1, 2008 No Longer Used
60505-2710-00 60505-2710 Granisetron Hydrochloride Granisetron Hydrochloride Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 27, 2008 Dec. 1, 2008 No Longer Used
60505-2642-03 60505-2642 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
60505-2642-01 60505-2642 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use

Found 10,000 results in 9 milliseconds — Export these results